Introduction:
Essential thrombocythemia (ET) is a form of myeloproliferative neoplasms
characterized by markedly increased mature megakaryocytes in the bone
marrow and sustained thrombocytosis of peripheral
blood.1, 2 Patients with ET, especially those with
mutations in the gene encoding Janus kinase 2 (JAK2 ), may
experience thrombohemorrhagic complications due to multifactorial
etiologies.3-6 Anagrelide is a non-leukemogenic
cytoreductive drug used for the treatment of ET in patients with a long
life-expectancy; however, it is associated with the incidence of various
cardiovascular side effects (5%–30%).7-9 Here, we
present an 18-year-old boy with ET who developed ST-segment elevation
myocardial infarction (STEMI) occurring after anagrelide initiation.